Drug news
FDA approves Truvada (emtricitabine/tenofovir disoproxil fumarate) for HIV Prevention- Gilead Sciences
The FDA has approved Truvada (emtricitabine/tenofovir disoproxil fumarate) from Gilead Sciences, the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truvada, taken daily, is to be used for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to reduce the risk of sexually-acquired HIV infection in adults at high risk.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.